{"id":"NCT02307513","sponsor":"Amgen","briefTitle":"A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's Disease","officialTitle":"A Phase 3, Multicenter, Randomized, Doubleblind, Placebo-controlled, Parallel Group Study, Followed by an Active-treatment Phase to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in the Treatment of Subjects With Active Behcet's Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-12-30","primaryCompletion":"2017-09-25","completion":"2020-07-17","firstPosted":"2014-12-04","resultsPosted":"2019-09-11","lastUpdate":"2021-07-22"},"enrollment":207,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Behçet's Syndrome"],"interventions":[{"type":"DRUG","name":"Apremilast","otherNames":["Otezla®","CC-10004"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Placebo / Apremilast","type":"EXPERIMENTAL"},{"label":"Apremilast","type":"EXPERIMENTAL"}],"summary":"The main objective of this study is to evaluate the efficacy and safety of apremilast in the treatment of oral ulcers in adults with active Behçet's disease (BD).","primaryOutcome":{"measure":"Area Under the Curve (AUC) for the Number of Oral Ulcers From Baseline Through Week 12 (AUC W0-12)","timeFrame":"Oral ulcers were assessed at weeks 0 (baseline), 1, 2, 4, 6, 8, 10, and 12 during the placebo-controlled period.","effectByArm":[{"arm":"Placebo","deltaMin":222.14,"sd":15.886},{"arm":"Apremilast 30 mg BID","deltaMin":129.54,"sd":15.943}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":63,"countries":["United States","France","Germany","Greece","Israel","Italy","Japan","Lebanon","South Korea","Turkey (Türkiye)"]},"refs":{"pmids":["37316690","35798511","31722152"],"seeAlso":["http://www.amgentrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":103},"commonTop":["Diarrhoea","Nausea","Headache","Upper respiratory tract infection","Viral upper respiratory tract infection"]}}